James Moore: Are we rolling over for foreign predators?
Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.Outlook How appropriate that the Business Secretary, Vince Cable, appears before the House of Lords Economic Affairs Committee to answer questions on foreign takeovers when there’s one in the offing.
It’s just that Shire Pharmaceuticals’ battle to stay out of the clutches of the US predator AbbVie hasn’t created quite the furore that Pfizer’s failed pop at AstraZeneca did, not least because neither of the parties carries much name recognition.
As with Pfizer, this isn’t just about drugs, although AbbVie could surely do with the diversity that a takeover of Shire would provide given its reliance on a single product. It’s about tax, and Shire says its stalker would quickly move its domicile to Britain if it succeeded with a bid, using a process known as “inversion” to keep its cash out of Uncle Sam’s hands.
Actually, it’s a bit hard for Shire to raise the Union flag in its defence because it just happens to be domiciled in Ireland, again for tax reasons. And, as Mr Cable pointed out, it’s difficult for the Brits to whinge about inversion given what successive governments have done to corporation tax rates with a view to attracting companies here.
But the question of whether it’s too easy to take over UK companies remains.
Britain would be foolish to adopt the tactics of the French, whose new powers to say “non” to just about any deal are probably illegal under European law, so we’ll see whether they’re tested. Regardless of that, however, they’re probably counter-productive; France might just as well say “non” to any foreign investor. Nor would it necessarily be a good thing to give ministers that sort of power here.
But Britain’s laissez-faire approach could be almost as damaging to the national interest. Professor John Kay, the economist who conducted a review of equity markets and long-term investment for the Government in 2012, argued that there is more ministers could do to make life hot for bad bidders.
He’s probably right, although such leverage needs to be used more effectively than in the case of AstraZeneca and Pfizer, when the so-called “binding undertakings” that Mr Cable and David Cameron keep banging on about were all but worthless.
Join our commenting forum
Join thought-provoking conversations, follow other Independent readers and see their replies
Comments